Finally, a trial planning to use the pan-PI3K inhibitor Copanlisib (BAY 80-6946) in patients with persistent or recurrent endometrial cancer with PIK3CA hotspot mutations was suspended (NCT02728258). The gene discussed is PIK3CA; the disease is endometrial cancer.